A Double-blind, Randomized, Parallel-group Multiple Dose Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
Latest Information Update: 27 Feb 2024
At a glance
- Drugs ALZ-101 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Alzinova
- 22 Feb 2024 Planned End Date changed from 31 Dec 2024 to 15 Jan 2025.
- 22 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 15 Jan 2025.
- 22 Feb 2024 Status changed to recruiting.